Working in partnership with investors, innovators, and pharmaceutical companies, Arrivo is always seeking out solutions for unmet medical needs. We strive to be the new standard for strategic asset selection and develop novel products through process that is both highly efficient and thoughtful.

Arrivo has built a portfolio of diverse late-stage drug candidates with the potential to be first-in-class or best-in-class. It is not just the products that are novel. Our entire approach is novel. Our unique form of drug development has resulted in a history of product successes and excellent returns.

The company stands on a solid foundation as our team has an average of more than 25 years of experience in drug development. We are propelled forward by our insatiable curiosity and drive to solve complex problems and help millions of patients globally.

SP-624 for major depressive disorder
DLX-105 for plaque psoriasis
DLX-2323 for inflammatory diseases
RABI-767 for severe acute pancreatitis